undamentalytics Newsletter
Sign in

Azitra, Inc. income statement

In fiscal 2025, Azitra, Inc. reported revenue of $0, down 100.0% on the year before and net income of −$11.0m, or −$2.25 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue0100
Research and development6455
General and administrative4466
Operating income−9−7−11−11
Interest expense0000
Income before tax−11−11−9−11
Income tax—000
Net income−11−11−9−11
Diluted EPS−$12.74−$54.98−$15.70−$2.25
Diluted shares (average)1m——5m
EBITDA−9−7−11−11

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AZTR vs CELZAZTR vs LYELAIM vs AZTR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Azitra, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Azitra, Inc.